Investigator-initiated trials see dramatic drop
Over the past five years, biopharmaceutical companies have invested significant resources building processes to track and manage investigator initiated trial (IIT) programs, in response to increased regulatory pressures. Yet the number of Investigational New Drug (IND) applications filed by independent investigators has declined, as grant spending for IIT programs has slowed at many companies.
Sponsors seeking preferred relationships with best sites
Productivity in the clinical trials industry has been trending negatively, as a reflection of more complex protocols and poor enrollment statistics of study sites. In the hope of shortening recruitment timelines and deflating study budgets, sponsors have been engaging larger numbers of sites to each enroll fewer patients in an attempt to more quickly hit their targets.
To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.